Skip to main content
Nicola Diny
© Anna Kunkel

News categories: Honors & Funding

New research group at the Institute of Clinical Chemistry and Clinical Pharmacology

We introduce: Dr. Nicola Diny

Nicola Diny is interested in the influence of the tissue environment on immune cell function. Recently recruited from the Francis Crick Institute (London / UK), Diny is now heading a junior research group at the Institute of Clinical Chemistry and Clinical Pharmacology (ICCCP) at the University Hospital Bonn. Together with her team, she is focusing on eosinophil tissue adaptation in the context of health and disease.


Ms Diny, you are heading a newly formed research group at the ICCCP. Could you briefly tell us about your main research interests?


My main interest is around understanding immune cell function in the tissue context. In particular, I want to explore how the eosinophil, a type of granulocyte, adapts to the local tissue niche, how this adaptation changes in the context of disease and how eosinophils interact locally with other immune and stromal cells. This is a new way of thinking about eosinophils, which are traditionally seen as endstage, cytotoxic effector cells.

A new way of thinking about eosinophils, that is actually based on findings you made during your time as a Postdoc at the Francis Crick Institute, right?


At the Crick, I studied intestinal eosinophils and discovered that these cells adapt to the local environment. This adaptation was partially driven by the transcription factor aryl hydrocarbon receptor, which changed the eosinophil transcriptome after cells enter the tissue. Eosinophil function changed towards a more immune-regulatory cell, increased interactions with the extracellular matrix and reduced their ability to degranulate. This opened up a new field of eosinophils tissue adaptation which I plan to investigate further.

That sounds like a promising, albeit very broad field. How exactly do you intend to address the questions that arise?


I will study the plasticity of eosinophils across the body and in the context of disease. Eosinophils are known to contribute to diseases like asthma and inflammatory bowel diseases (IBD) but more recently beneficial roles in bacterial infections, tissue regeneration and cancer have been discovered as well. This highlights key questions on how eosinophil function changes in different diseases and across tissues. I recently established that eosinophils undergo tissue adaptation in the small intestine as part of their homeostatic regulation. To study eosinophil plasticity, I will create an atlas of eosinophils across tissues in mice, explore the regulation of intestinal eosinophils and how it is changed during inflammation, and study human eosinophil function in the context of health and diseases like IBD. To achieve this, my group will use spatial and single cell technologies in addition to genetic models to explore eosinophil functions within tissues.

We are more than happy to welcome you at research site here in Bonn. What was particularly important to you when choosing the location?


For me, the opportunity for translational research with access to patient samples and clinical collaborations was an important reason to choose the University Hospital Bonn. At the same time, I was keen to be integrated into the broad and excellent immunology research that exists within the ImmunoSensation cluster. I look forward to exciting collaborations with my new colleagues.

(Interview with Dr. Nicola Diny, Bonn, June 19th, 2023)



Short biography

Nicola Diny studied Biomedicine and Biotechnology in Vienna and Molecular Medicine at the Charité Berlin. She obtained her PhD from Johns Hopkins University where she worked in the group of Noel Rose and Daniela Cihakova to understand how eosinophils drive inflammation and chronic adverse remodelling of the heart. For this work she received a Predoctoral Fellowship from the American Heart Association and multiple basic and translational research awards. Nicola Diny continued to study eosinophil tissue functions and joined Gitta Stockinger's group at the Francis Crick Institute for her postdoc, supported by an EMBO Postdoctoral Fellowship and then a Sir Henry Wellcome Fellowship. She is now continuing her work on eosinophil tissue adaptation heading a Junior Research Group at the Institute of Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn.


Contact

Dr. Nicola Diny

Institute of Clinical Chemistry and Clinical Pharmacology

University Hospital Bonn

email: nicola.diny@uni-bonn.de

Related news

News Marvin Supercomputer

News categories: Honors & Funding

Two years of the Marvin Supercomputer: Researchers in Bonn present their projects

Two years after it went into operation, the University of Bonn celebrated the Marvin Supercomputer with a community event at the Research and Technology Center for Detector Physics (FTD). Researchers from various disciplines presented projects that had been carried out using high-performance computing and used the event as an opportunity for interdisciplinary exchange. A team lead by ImmunoSensation³ members Prof. Dr. Michael Hölzel (Institute of Experimental Oncology) and PD Dr. Gregor Hagelueken (Institute of Structural Biology) use Marvin to design new proteins.
View entry
Award Ceremony, SxDiagnostics

News categories: Honors & Funding

start2grow start-up competition awards “SxDiagnostics”

The “SxDiagnostics” project from the University of Bonn and the University Hospital Bonn (UKB) prevailed against over 100 competing teams in the start2grow competition and placed in the (shared) 4th to 10th spots. Start2grow is organized nationwide by the Dortmund Economic Development Agency and celebrated its 25th anniversary this year.
View entry
Gut

News categories: Honors & Funding

Millions in funding for the new MikrobiomProCheck research project

The human gut microbiome is as unique as a fingerprint. It plays a central role in chronic inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis. Yet its potential for diagnostics and personalized therapy for patients remains untapped. The MikrobiomProCheck research project aims to change this. To this end, the Leibniz Institute for Analytical Sciences (ISAS), the Universities of Bonn, Bielefeld, and Duisburg-Essen, Biofidus AG, and Lead Discovery Center GmbH are receiving approximately 3.4 million euros from the state government of NRW and the European Union.
View entry

Back to the news overview